Last reviewed · How we verify
NCT00316732
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
trial testing IPSS Questionnaire in Prostatic Hyperplasia in 173 participants. Completed in 19 December 2006.
19 December 2006
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 173 |
| Start date | 25 October 2004 |
| Primary completion | 19 December 2006 |
| Estimated completion | 19 December 2006 |
| Sites | 27 locations across United Kingdom |
Drugs / interventions tested
- IPSS Questionnaire
- EQ-5D Questionnaire
Conditions studied
- Prostatic Hyperplasia — all drugs for Prostatic Hyperplasia →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Eligibility, male only, with Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00316732
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostatic Hyperplasia
Currently open trials in the same condition.
- NCT06242119 — Clinical Application of the J-PET Scanner Prototype · recruiting
- NCT06161506 — Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer · Phase 2 · recruiting
- NCT06209307 — Pelvic Floor Physical Therapy to Reduce Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate · NA · active not recruiting
- NCT06001619 — Prostate Medication, Metabolism and Gut Microbiota · Phase 4 · recruiting
- NCT03354416 — Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00316732 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 16 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00316732.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing